Aims Erythropoietin, a glycoprotein hormone is produced by the kidney and targeted to erythrocyte precursors. Recombinant human erythropoietin (Epoetin b) has been utilized for therapeutic purposes in renal anaemia or anaemia occurring after auto blood donation or chemotherapy. The administration routes for erythropoietin are normally subcutaneous or intravenous. No population pharmacokinetic analysis, however, has been performed following subcutaneous administration with consideration given for endogenous production. Methods In the present study, we have attempted to analyze the pharmacokinetics of erythropoietin after subcutaneous administration in healthy adult male volunteers by using the Nonlinear Mixed Effect Model program (NONMEM) with a model including endogenous erythropoietin production. Results It has been established that the final estimation of the population mean values of the absorption rate constant (k a ), the elimination rate constant (k e ), the distribution volume ( V ) and the endogenous production are 0.0430 h −1 , 0.206 h −1 , 3.14 l and 15.7IU h −1 , respectively. For the circadian rhythm of endogenous production, the amplitude was calculated as 9.86% and the peak appeared around 24.00 h.
Introduction endogenous production of erythropoietin should have a circadian rhythm. Erythropoietin, a 34 000-Dalton glycoprotein hormone, is produced by the kidney and targeted to erythroid progeniIn the present study, we have attempted to analyze the pharmacokinetics of erythropoietin after subcutaneous tors. Recently, recombinant DNA technology has made it possible to use recombinant human erythropoietin (Epoetin administration in healthy adult male volunteers by using the Nonlinear Mixed Effect Model program (NONMEM) with b) for therapeutic purposes in renal anemia or anemia occurring after auto blood donation or chemotherapy on a one-compartment open model with first-order absorption, including endogenous erythropoietin production. neoplasm. Epoetin b is confirmed to be identical with natural human erythropoietin in physicochemical, immunological and biological quality [1, 2] . Methods Erythropoietin is mainly given by intravenous and subcutaneous administration. There is no reported population pharmacoStudy protocol and subjects kinetic analysis, following subcutaneous administration with
This study was performed in order to confirm the consideration given for the endogenous production.
bioequivalence of two kinds of Epoetin b formulations. The The changes in plasma erythropoietin concentration are results showing that their pharmacokinetic properties are known to exhibit a circadian rhythm [3] . The regulation identical based on the evidence of the moment analysis mechanism of erythropoietin production is thought to method, have already been reported [6] . depend on the partial pressure of oxygen of the blood in According to the protocol, the subjects were administered the kidney [4] , and the blood flow in the kidney has a 1500IU or 3000IU of Epoetin b subcutaneously in the forearm at 09.00 h, twice at an interval of 2 weeks. and after physical examinations. Admission criteria included Recovery test: Two human serum samples (11.6 and 44.7IU l −1 ) to which epoetin b had been added at normal laboratory parameters, including complete blood count, platelet count, prothrombin time and activated partial concentrations of 4 to 128IU l −1 were assayed. The assays showed a recovery from 89.6 to 104.4%. thromboplastin generation time, as well as the absence of any evidence of clinically significant cardiovascular, renal, Test with substitute matrix: The r.i.a. was run at eight concentrations (4.0 to substitute matrix: 512.0IU l −1 ) nine hepatic, metabolic, gastrointestinal, neurologic, or endocrine disorders. Each subject gave his written consent after having times each and the CV ranged from 0.9 to 6.7%. The limit of detection (LOD) was 2.1IU l −1 (calculated from the been informed of the contents of the study protocol, which had been approved by the Institutional Review Board of value of (mean-2 s.d.) of the count at 0IU l −1 ).
the clinical centre Kannondai Clinic (Ibaraki, Japan). Subjects were divided into two groups, with 16 subjects Pharmacokinetic and statistical model assigned to the 1500IU and 32 to the 3000IU dose group, respectively.
The pharmacokinetics of erythropoietin have previously Particulars such as age, height, weight, were not signifibeen described using a two-compartment open model in cantly different between the two groups. The background rats [9] . However, the model had been selected for data are shown in Table 1. intravenous administration, and the C max was much higher than that observed following subcutaneous administration.
After preliminary examination, we adopted a one-
Sample collections and drug analysis
compartment open model with a first order absorption, Venous blood (3 ml) was collected into heparinized tubes including constant endogenous erythropoietin production, 1 h before and at 3, 6, 9, 12, 15, 24, 36, 48, 72, 96 h after to describe the plasma concentration-time profile of erythroeach administration. Blood samples were centrifuged for poietin. We also assumed that the absorption rate constant 10 min after collection at room temperature and sera were k a is smaller than the elimination constant k e , because the harvested and stored frozen until analysis.
half-life period of plasma erythropoietin is about three times Plasma erythropoietin was assayed by using the r.i.a.
longer following subcutaneous administration compared to method with an antiserum prepared from rabbit immunized intravenous administration [10] [11] [12] [13] [14] . The model is referred with Epoetin b [7] . Erythropoietin standard and serum to as being a flip-flop phenomenon. sample (100 ml) were incubated for 16 h at room temperature Taking k aj , k ej , V j , E j and F j as the absorption rate with 100 ml of 50 000 fold diluted antiserum and 200 ml constant, the elimination rate constant, the distribution pH 7.4 phosphate buffer saline solution containing 1% BSA volume, the average of endogenous erythropoietin proand 0.05% Tween 20. This buffer solution was used also as duction and bioavailability, respectively, in the j-th individa diluent for all dilution steps. 100 ml (10 000 counts min END ij =E j (1+Amp j sin(2pt i /24+t 0j )) tube. After 4 h of subsequent incubation at room temperature, 250 ml of Immunobeads solution (Bio-Rad Labs; ISA (END ij =E j (1+Amp j sin(2p(6−T i +Tpeak j )/24), goat anti-rabbit immunoglobulin) was added, and stood for T i =t i +9, Tpeak j =15−24/2pt 0j (hours after midnight)) (1) 1 h at room temperature. The mixture was then centrifuged, with addition of 2 ml of 0.9% NaCl solution, at 3000
rev min −1 for 10 min. The supernatant was aspirated off, and the radioactivity of the precipitate was measured with a c-counter.
Assessment of precision of the serum erythropoietin r.i.a. was performed and the result were as below [8] .
Within-run precision: R.i.a. was run on three human serum samples (25.5 to 127.4IU l −1 ) 10 times each. The = Dose k aj (exp(−k ej t i )−exp(−k aj t i )) (V j /F j )(k aj −k ej ) CV ranged from 4.5 to 5.7%.
Between-run precision: R.i.a. was run on three human serum samples (25.5 to 138.2IU l −1 ) on 5 consecutive days.
2) The CV ranged from 1.9 to 6.7%.
where t i is the time after 1st administration, C ij and END ij /F j Assessment of each factor was performed by the backward selection method after the following procedure. All of the are the plasma erythropoietin concentration and the apparent endogenous erythropoietin production in the j-th individual suspected factors which might have the correlation to the posterior estimates of pharmacokinetic parameters computed at time t i , t 0j and Amp j are the constants describing the phase and amplitude of the circadian rhythm in the j-th by using the basic model, were added to the description of k : aj , k : ej , V j /F j , and E j /F j as follows, individual.
To quantify the inter-and intra-individual variabilities,
the nonlinear mixed effect model was constructed for data analysis. The additive error and proportional error models where X j is k : aj , k : ej , V 9 j or E j , and P 1 , P 2 , … are parameters to be estimated and FC 1 , FC 2 , … are factors to be tested are typical parametric models to describe a distribution of errors. On the basis of a preliminary study's results based on which are, body weight, height, age and laboratory test items, serum creatinine, albumin etc. the objective function, we chose the proportional error model for both of the intra-individual and inter-individual error model,
Population pharmacokinetic parameters estimates k ej =k : ej (1+g ke,j ) Figure 1 shows the changes in plasma erythropoietin
concentration for all volunteers. As shown in Figure 2 and Table 2 , plasma erythropoietin concentrations significantly (ENDij/F j )=(END ij /F j ) (1+END/F,j) increased in the 3000IU dose group. This suggests that some C ij =C 9 ij (1+e ij ) (3) pharmacokinetic parameters changed during the period between the 1st and the 2nd administration. Concerning the where g ka,j , g ke,j , g V,j and g END/F,j are individual random model assumed, the reason why such a change occurred perturbations from the population mean parameters that are could be (1) that endogenous erythropoietin production independent and normally distributed with mean zero and increased, (2) that k e decreased or (3) that F or k a changed.
To evaluate this assumption, these hypotheses of (1) and k : aj , k : ej , V j /F j , and END ij /F j represent typical values of the (2) were examined on a preliminary basis by using a basic absorption rate constant, elimination rate constant, apparent model, including only body weight as a factor in V. As a distribution volume and apparent endogenous erythropoietin result, the objective functions were 4902.900 in (1) and production predicted by the regression Equation 4. e ij refers 4926.301 in (2). Also, as shown in Figure 2 , the hypothesis to independent identically distributed errors with mean zero
(1) was more likely, because the shapes of the peaks after and variances s 2 for plasma concentrations. C ij is a measured the 1st and 2nd administrations were similar. If k e changes concentration, and C 9 ij is a value calculated by using the between 1st and 2nd administration, the two peak shapes individual parameter values.
should be different. Hypothesis (3) seems to be unlikely. Even if the pharmacokinetic properties of subcutaneous tissue could be changed by only one administration, the Data analysis tissue should not be affected over so broad an area, that the 2nd administration might not be performed in the same place. Computation was carried out using the NONMEM program Version IV Level 1.1 and a NM-TRAN preprocessor with There was no obvious evidence to prove the hypothesis, however, so that analysis was performed on hypothesis (1). user supplied PRED subroutine on a Hewlett Packard APOLLO 9000 model 710 workstation computer. For the In the following analysis, the average for endogenous erythropoietin production during a whole day for all computation of population parameter estimates, the FirstOrder method (FO) was used. subjects, is expressed as E 1 (average around 1st administration), E 2 (average around 2nd administration in 1500IU The likelihood ratio test was used for assessing which covariates were able to influence the pharmacokinetics of dose group) and E 3 (average around 2nd administration in 3000IU dose group). erythropoietin in this healthy volunteer population. NONMEM computes the minimum value of the objective First, posterior estimates of the pharmacokinetic parameters k a , k e , V d and E/F were calculated by using the basic function, which is equal to the negative value of twice the log likelihood on the assumption that distributions of model, including only body weight as a factor in V/F. Then, the correlation between these pharmacokinetic random variables are normal [15] . A null hypothesis can be examined by comparing the values of the objective function,
parameters and factors to be tested was examined. Secondly, the factors which were suspected to influence the pharmacobetween allowing the parameter(s) of interest to be freely estimated and fixing the parameter(s). This difference in the kinetic parameters, were included by using Equation 4. These four factors seemed to be correlated with these values of the objective function (−2LL) is asymptotically distributed as x 2 with degrees of freedom equal to the pharmacokinetic parameters, as shown in Table 3 . The full model, including these five factors, was tested number of parameters that were fixed to hypothesized values. A difference of 7.879 in the value of the objective by the single reduction method, and three meaningful factors selected as the 1st selection result. In the 2nd selection, it function with one degree of freedom was used as being statistically significant ( P<0.005) since multiple regression was confirmed that all three factors influence the pharmacokinetic parameters significantly. testing was performed in this analysis. As a result of the 2nd selection, each parameter was (The values in parentheses are calculated using the mean value for the subjects) estimated as shown in (2) in mathematThe equation suggests that the endogenous production ical terms. peak occurred at 0.15 h and that the amplitude was 9.86%.
There is a good correlation between the predicted concentration curve and the observed concentration values (Figure 2) . Figure 2 shows a good curve fit and indicates
Estimation of the true values of V and endogenous production that the model is suitable for analysis of subcutaneous erythropoietin administration.
By using only the data from this subcutaneous administration study, it is not possible to estimate the pharmacokinetic The high correlation between the predicted values and the observed values is shown in Figure 3 , and it should parameters of the true distribution volume and endogenous erythropoietin production. Thus, we obtained the same data prove this model was suitable to demonstrate the pharmacokinetics of erythropoietin after s.c.
on AUC as those reported elsewhere in the literature [12, 13] , on intravenous Epoetin b administration studies. The plot of WRE (weighted residuals) vs time is shown in Figure 4 . The distribution of WRE at each time point
For the calculation of the s.e. for the true values, the drug should be administered both i.v. and s.c. to same was relatively symmetric and not distorted, and it did not change largely along the time course. subject. However, the population means of the true values of V and END (V /F and END/F) which were calculated The correlation between Bayes estimated pharmacokinetic Observed values (IUl by the mean of F have a considerable accuracy, because of the relatively small inter-individual variability of F.
differences in the values of k a , k e and the apparent The results are shown in Table 5 . The population mean endogenous production around 1st administration between values of F, V and true endogenous erythropoietin the two dose groups. production for the 1st administration period were estimated as 21.9 (%), 3.14 (l) and 15.7 (IU h −1 ), respectively. Discussion The estimated k a and k e which were also calculated by using the Bayesian estimated values, were 0.0430±
Recently, population pharmacokinetic studies have been successfully performed to detect the pharmacokinetic proper-0.002 h −1 and 0.206±0.004 h −1 . There were no significant ties of many drugs in the clinical field. However, references concentration of erythropoietin was reported to appear was 20.00 h [3] . to pharmacokinetic analysis of endogenous substances after subcutaneous administration are scarce.
We assumed an increase in endogenous production between the 1st and 2nd administrations for the 3000IU Erythropoietin, which we analyzed in this study, is a glycoprotein hormone mainly produced in the human dose group. The increase in apparent endogenous production was 76.1±5.1 to 91.6±5.9 (IU h −1 , mean±s.e.mean), and kidney. Several papers have reported the pharmacokinetics of erythropoietin after intravenous administration on the it was nearly double the amplitude (9.86%×2, 15.0IU h −1 ) following a circadian rhythm. Therefore, the change was basis of a two compartment open model in animals. For subcutaneous administration, however, the increase in plasma not so large. On the other hand, if k e decreased, the shapes of the peaks after the 1st and 2nd administrations should be concentration is nearly double the concentration before administration. We therefore selected a one-compartment different. Several papers on repeated intravenous erythropoietin administration studies, reported an increase in ke rather open models and it proved suitable.
The changes in plasma erythropoietin concentration are than decrease [13, 14] . The objective function is larger when k e is assumed to increase rather than on the assumption known to exhibit a circadian rhythm [3] . The regulation mechanism of erythropoietin production is thought to of a decrease in endogenous production. The estimated pharmacokinetic parameters were identical depend on the partial pressure of oxygen of the blood in the kidney [4] , and the blood flow in the kidney has a to those reported for intravenous erythropoietin administration studies [12, 13] . In this study, the population means circadian rhythm in normal individuals [5] . For this reason, we included its endogenous production in accordance with of the elimination rate constant k e and the true distribution volume V were estimated as 0.206 h −1 and 3.14 (l), a circadian rhythm in this model. It was possible to substantiate this and to show that the endogenous production respectively. The values of k e and V calculated from the paper on intravenous Epoetin b administration studies, were peak appeared at 24.00 h. The time the peak of the plasma 0.192±0.036 h −1 and 4.03±0.47 l (mean±s.e.mean n= patients. Once the pharmacokinetics of erythropoietin in patients with renal anaemia, myelodisplastic anaemia or 16), respectively [12, 13] . These values are very similar to those estimated in our study.
other diseases, has been established, the result would no doubt open the way for more suitable therapeutics. For There was no significant difference in the Bayesian estimated values of k a and k e and the apparent endogenous example, some low-or non-responders to erythropoietin treatment are occasionally observed in renal anaemia patients production around 1st administration between the 1500IU and 3000IU dose groups. This suggests that the pharmacoand this analysis could be helpful in identifying the reason for the absence of the response. This analysis could also be kinetics of erythropoietin is not dependent on dose and there is no important distortion in this analysis.
useful in developing a therapy for myelodisplastic anaemia. This analysis suggests that there is a relationship between the serum creatinine and age influences on k e . Studies on References rats [16] suggest that the organs in which erythropoietin is eliminated are the kidney and the bone marrow. Serum half-life period in the case of subcutaneous as compared 1-28. with intravenous administration. The hypothesis was also elimination and its circadian rhythm pattern. However, the 445-479. pharmacokinetic model employed in this report, can be seen 
